Search research articles
Contact Us
Filters
Showing results (121-130 of 271) with videos related to
Page
of 28
Sort By:
Pediatric Hematology and Oncology
|
December 17, 2021
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
Stephanie M Smith, Shiqi Zhang, Vandana Sundaram, et al.
Pediatric Blood & Cancer
|
July 6, 2019
A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation
Anne E Kazak, Avi Madan Swain, Kimberly Canter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2007
The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate
Rui Yang, E Anders Kolb, Jing Qin, et al.
European Journal of Medical Genetics
|
January 4, 2024
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression
Kristian L Juul-Dam, Neerav N Shukla, Todd M Cooper, et al.
Pediatric Blood & Cancer
|
July 21, 2023
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms
Todd M Cooper, Todd A Alonzo, Sarah K Tasian, et al.
Pediatric Blood & Cancer
|
August 26, 2015
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Michael Roth, David M Barris, Sajida Piperdi, et al.
Bioinformatics Advances
|
May 30, 2023
Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and <i>ex vivo</i> data
Mauricio H Ferrato, Adam G Marsh, Karl R Franke, et al.
Pediatric Blood & Cancer
|
May 4, 2011
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
Christopher L Morton, John M Maris, Stephen T Keir, et al.
Pediatric Blood & Cancer
|
June 2, 2011
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program
E Anders Kolb, Richard Gorlick, John M Maris, et al.
Pediatric Blood & Cancer
|
July 9, 2015
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program
C Patrick Reynolds, Min H Kang, John M Maris, et al.
Page
of 28
Search research articles
Search
Showing results (121-130 of 271) with videos related to
Sort By:
Page
of 28
Pediatric Hematology and Oncology
|
December 17, 2021
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
Stephanie M Smith, Shiqi Zhang, Vandana Sundaram, et al.
Pediatric Blood & Cancer
|
July 6, 2019
A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation
Anne E Kazak, Avi Madan Swain, Kimberly Canter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2007
The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate
Rui Yang, E Anders Kolb, Jing Qin, et al.
European Journal of Medical Genetics
|
January 4, 2024
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression
Kristian L Juul-Dam, Neerav N Shukla, Todd M Cooper, et al.
Pediatric Blood & Cancer
|
July 21, 2023
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms
Todd M Cooper, Todd A Alonzo, Sarah K Tasian, et al.
Pediatric Blood & Cancer
|
August 26, 2015
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Michael Roth, David M Barris, Sajida Piperdi, et al.
Bioinformatics Advances
|
May 30, 2023
Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and <i>ex vivo</i> data
Mauricio H Ferrato, Adam G Marsh, Karl R Franke, et al.
Pediatric Blood & Cancer
|
May 4, 2011
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
Christopher L Morton, John M Maris, Stephen T Keir, et al.
Pediatric Blood & Cancer
|
June 2, 2011
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program
E Anders Kolb, Richard Gorlick, John M Maris, et al.
Pediatric Blood & Cancer
|
July 9, 2015
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program
C Patrick Reynolds, Min H Kang, John M Maris, et al.
Page
of 28